INTRODUCTION
============

Diverse functions of the actin cytoskeleton are supported by a variety of actin-regulatory proteins ([@B68]). Among them, tropomyosin serves as a major regulator of actin functions in fungi and metazoans ([@B53]; [@B67]; [@B20]; [@B36]; [@B39]). Tropomyosin is a coiled-coil dimer that binds along the side of actin filaments and influences actomyosin contractility and actin filament dynamics ([@B4]; [@B56]; [@B78]; [@B40]; [@B69]; [@B91]). It regulates actin--myosin interaction in an isoform-specific manner ([@B55]; [@B29]) and stabilizes actin filaments by inhibiting actin depolymerizing factor/cofilin-mediated severing ([@B10]; [@B65]). While tropomyosin inhibits Arp2/3-­dependent actin nucleation and branching ([@B11]), it promotes formin-dependent actin elongation ([@B92]; [@B77]; [@B87], [@B86]; [@B1]). Classically, tropomyosin has been well characterized as a regulator of muscle contraction. In striated muscles, tropomyosin mediates Ca^2+^-dependent conformational changes of the troponin complex to activate or inhibit actin--myosin interaction ([@B22]; [@B79]; [@B27]). In nonmuscle cells, tropomyosin is involved in a wide range of actin-dependent events including cell migration, cytokinesis, and morphogenesis ([@B36]). In metazoan species, the presence of multiple tropomyosin isoforms with distinct functions is associated with the roles of tropomyosin in a variety of cellular processes ([@B37], [@B36]). Nevertheless, the functions and regulatory mechanisms of tropomyosin isoforms are not fully characterized.

Increased diversity of tropomyosin isoforms correlates with the evolution of complexity in cells and tissues ([@B36]). The budding yeast *Saccharomyces cerevisiae* has two tropomyosin isoforms from separate genes ([@B21]) that give rise to different effects on actin--myosin interaction ([@B42]) and formin function ([@B1]). Contrastingly, mammalian species have four tropomyosin genes that produce over 40 isoforms by alternative splicing ([@B74]; [@B30]). In addition to the tissue-specific expression of tropomyosin isoforms, many isoforms are sorted to different subcellular regions ([@B81]; [@B13]; [@B28]). During stress fiber formation, at least four tropomyosin isoforms contribute to organizing the assembly of distinct compartments of stress fibers ([@B85]). In neurons, several tropomyosin isoforms localize to different actin-rich compartments and have unique effects on neuronal cell morphology ([@B72]; [@B18]). In striated muscle, major sarcomeric tropomyosins localize along the thin filaments, whereas the minor isoforms Tpm3.1 (Tm5NM1) and Tpm4.2 localize to narrow regions adjacent to the Z-lines ([@B73]; [@B90], [@B89]). Additionally, novel tropomyosin isoforms with unexpected functions were discovered in *Drosophila*: these functions include important roles in mitotic spindles ([@B31]), microtubule-dependent mRNA localization ([@B88]), and intermediate filament-like cytoskeletal functioning ([@B17]). Notwithstanding our current understanding of isoform diversity, functions of many other tropomyosin isoforms remain unknown. Therefore, further studies on tropomyosin isoforms may reveal unexpected functions.

The nematode *Caenorhabditis elegans* has a single gene for tropomyosin, *lev-11* (also known as *tmy-1*), which has been reported to produce four isoforms through the utilization of two separate promoters and alternative splicing ([@B45]; [@B3]). *lev-11* mutants were originally isolated from a screen for levamisole-resistant strains ([@B51], [@B52]). Levamisole, an agonist of the acetylcholine (ACh) receptor, induces contraction and paralysis in wild-type worms. However, *lev-11* mutants remain motile in the presence of levamisole. Strong loss of function or null mutation of *lev-11* causes severe [p]{.ul}aralysis and embryonic [a]{.ul}rrest at the [t]{.ul}wo-fold stage (Pat phenotype) ([@B95]). In the adult body wall muscle, which is obliquely striated muscle ([@B63]), RNA interference (RNAi) of *lev-11* causes partial paralysis, disorganization of sarcomeres ([@B65]; [@B96]) and defective muscle arm development ([@B19]). *lev-11* is also important in the reproductive system through its role in regulating the contractility of male sex muscle ([@B35]) and hermaphroditic gonadal myoepithelial sheath ([@B62]). However, complex splicing patterns of *lev-11* and the functional significance of the *C. elegans* tropomyosin isoforms remain elusive.

In this study, we cloned a novel *C. elegans* tropomyosin isoform, LEV-11O, containing a newly identified alternative *lev-11* exon ([@B48]) and found that this exon is predominantly utilized in a subset of head muscle cells. Mutational and transgenic analyses suggest that tropomyosin isoforms produced by alternative splicing differentially affect muscle contractility in the head and main-body regions. These results suggest that alternative splicing of the *lev-11* tropomyosin gene is a key to differentiating the body wall muscle cells in the head and main-body regions.

RESULTS
=======

A newly characterized alternative exon of *lev-11* is included in a novel high-molecular-weight tropomyosin isoform
-------------------------------------------------------------------------------------------------------------------

The structure of the *C. elegans lev-11* gene ([Figure 1A](#F1){ref-type="fig"}) is fairly complex. First, it has two promoters ([Figure 1A](#F1){ref-type="fig"}): the upstream promoter (promoter 1) drives transcription from exon 1 (E1) to express high-molecular-weight isoforms, whereas the downstream promoter (promoter 2) drives transcription from exon 3b (E3b) to express low-molecular-weight isoforms ([@B45]; [@B3]). Second, the *lev-11* gene contains multiple alternatively spliced exons 4 (a and b), 5 (a--c), and 9 (a--c) ([Figure 1A](#F1){ref-type="fig"}) ([@B45]; [@B3]). Additionally, gene models in WormBase ([www.wormbase.org](http://www.wormbase.org)) suggested that exon 7 is also duplicated ([Figure 1A](#F1){ref-type="fig"}, shown in green). The sequence of an expressed sequence tag clone (yk783g10) and recent deep sequencing of poly(A)^+^ RNAs from synchronized L1 larvae confirmed the use of exon 7a (E7a) ([@B48]), which is the same length (139 nt) as exon 7b (E7b; previously reported as exon 7) with 71% nucleotide sequence identity and is conserved in the genus *Caenorhabditis* (Supplemental Figure S1).

![Characterization of mutually exclusive seventh exons of the *C. elegans lev-11* tropomyosin gene. (A) Structure of the *lev-11* gene is shown schematically (top) with numbered boxes indicating exons. Recently characterized alternative exons 7a and 7b are shown in green. Below the gene structure are splicing patterns of LEV-11A/CeTMI, a newly identified isoform, LEV-11O, and three previously characterized isoforms, LEV-11D/CeTMII, LEV-11E/CeTMIII, and LEV-11C/CeTMIV. Coding and noncoding regions are shown in orange and light yellow, respectively. Note that exon 9c is used in all known isoforms either as a coding region (LEV-11A and LEV-11O) or as a noncoding region when 9a or 9b is used as a coding region (LEV-11C, LEV-11D, and LEV-11E). (B) Analysis of *lev-11* mRNAs by RT-PCR. Total RNAs from synchronized wild-type L1 larvae were subjected to RT-PCR with indicated primer pairs and cycle numbers, and the PCR products were analyzed with a 2100 BioAnalyzer (Agilent). DNA size markers are shown on the left. Results are shown in gel-like presentations. Exon combinations of representative bands *a--d* are shown below. Multiple bands in E7b/E9c (lane 6) were cloned and sequenced, and the exon combinations are indicated on the right. Asterisks indicate artificial PCR products due to excessive cycles. (C) Alignment of amino acid sequences encoded by exons 7a and 7b. Identical residues are indicated with black backgrounds. Point mutations in *lev-11(gk334531)* and *lev-11(x12)* are shown at the top and bottom of the sequences, respectively. (D) Probability of coiled-coil formation (0--1) was calculated from the full-length sequences of LEV-11A and LEV-11O by COILS ([@B54]), and plots of exon 7-coded regions are shown.](mbc-29-1075-g001){#F1}

Splicing patterns in relation to the E7a/E7b selection were analyzed by reverse transcription-PCR (RT-PCR) ([Figure 1B](#F1){ref-type="fig"}). With the E1/E7a and E1/E7b primer pairs, single bands were detected ([Figure 1B](#F1){ref-type="fig"}, lanes 1 and 2), and both of them included E1/E2/E3a/E4b/E5b/E6, indicating that E7a and E7b are included in high-molecular-weight isoforms in a mutually exclusive manner. However, with the E3b primer, a band was detected for the E3b/E7b pair ([Figure 1B](#F1){ref-type="fig"}, lane 4) but not for the E3b/E7a pair ([Figure 1B](#F1){ref-type="fig"}, lane 3), indicating that E7a is not included in a low-molecular-weight isoform. With the E7a/E9c primer pair, only a single band, which excluded E9a and E9b (E7a/E8/E9c), was amplified ([Figure 1B](#F1){ref-type="fig"}, lane 5). In contrast, three expected fragments corresponding to E7b/E8/E9c, E7b/E8/E9a/E9c, and E7b/E8/E9b/E9c were amplified with the E7b/E9c primer pair ([Figure 1B](#F1){ref-type="fig"}, lane 6). With an effort to characterize a full-length cDNA containing E7a, we obtained clones for a novel isoform, LEV-11O (E1/E2/E3a/E4b/E5b/E6/E7a/E8/E9c) ([Figure 1A](#F1){ref-type="fig"}), which was previously only predicted from a possible exon combination (GenBank accession \# NM_001313528). LEV-11O is a high-molecular-weight tropomyosin isoform (284 amino acids) that is most similar to LEV-11A (E1/E2/E3a/E4b/E5b/E6/E7b/E8/E9c), with differences only in the E7a/E7b-encoded region ([Figure 1C](#F1){ref-type="fig"}). Both E7a and E7b encode 46 residues, and their amino acid sequences show 78% identity ([Figure 1C](#F1){ref-type="fig"}). These sequences are invariable among the examined *Caenorhabditis* species, suggesting their functional significance. The E7a- and E7b-encoded sequences are mostly different in the second half ([Figure 1C](#F1){ref-type="fig"}) with notable substitutions of acidic (E215 and D228) and hydrophobic (I219 and F229) residues in E7a in place of polar residues (Q215, S219, S228, and S229) in E7b. Interestingly, prediction of coiled-coil formation by COILS ([@B54]) suggests a low probability of coiled-coil formation at the E7a-encoded residues 218--224 of LEV-11O ([Figure 1C](#F1){ref-type="fig"} underlined residues and 1D). Therefore, these isoforms may possess a conformational difference.

Alternative exons, E7a and E7b, of the *lev-11* gene are differentially selected in the head and main-body regions of body wall muscles
---------------------------------------------------------------------------------------------------------------------------------------

We utilized fluorescence reporter systems for alternative splicing to analyze the selection pattern for E7a/E7b in vivo. We constructed a pair of reporter minigenes in which a *lev-11* genomic fragment spanning from E6 through E8 was connected in-frame to the cDNA for mCherry (E7a reporter) or EGFP (E7b reporter) ([Figure 2, A and B](#F2){ref-type="fig"}; [@B47]). A stop codon was introduced in E7b of the mCherry construct, such that only selection of E7a would result in mCherry expression ([Figure 2A](#F2){ref-type="fig"}). Likewise, a stop codon in E7a of the EGFP construct would result in EGFP expression only when E7b was selected ([Figure 2B](#F2){ref-type="fig"}). When these minigenes were ubiquitously expressed, only a small number of body wall muscle cells at the head predominantly expressed E7a-mCherry ([Figure 2, C and E](#F2){ref-type="fig"}), whereas the other tissues expressed E7b-EGFP ([Figure 2, D and E](#F2){ref-type="fig"}). To determine the E7a/E7b selections more clearly in the body wall muscle cells, these minigenes were expressed under the control of the *myo-3* promoter ([Figure 2, G--I](#F2){ref-type="fig"}), which is active in all body wall muscle cells ([@B61]). These muscle-specific reporters showed that the two most anterior muscle cells in each muscle quadrant strongly expressed E7a-mCherry ([Figure 2G](#F2){ref-type="fig"}, cells 1 and 2) but only weakly expressed E7b-EGFP ([Figure 2H](#F2){ref-type="fig"}) (note that *C. elegans* body wall muscle cells are mononucleated and do not fuse). The two cells in the second row ([Figure 2G](#F2){ref-type="fig"}, cells 3 and 4) weakly expressed both E7a-mCherry and E7b-EGFP. The rest of the body wall muscle cells ([Figure 2, H and I](#F2){ref-type="fig"}) and vulval muscle cells (not shown in the figure) predominantly expressed E7b-EGFP. These cells also weakly expressed E7a-mCherry ([Figure 2, G and I](#F2){ref-type="fig"}). The weak E7a-mCherry signals throughout the muscle indicate that selection of E7a from the reporter minigenes can occur as minor events even when selection of E7b is predominant. Quantitative analysis of the fluorescence signals further confirmed these differential selection patterns of E7a and E7b in the head region ([Figure 2, J and K](#F2){ref-type="fig"}). Similar patterns were observed in muscle cells of multiple transgenic isolates with both ubiquitous and muscle-specific promoters (our unpublished data).

![Fluorescence splicing reporter analysis for *lev-11* E7s. (A, B) Schematic illustration of reporter minigenes for *lev-11* E7a (LEV-11-E6E7aE8-GGS6-mCherry) (A) and *lev-11* E7b (LEV-11-E6E7bE8-GGS6-EGFP) (B). Structures of mRNA isoforms are indicated below each minigene. The cDNA cassettes and the predicted ORFs for mCherry and EGFP are colored in magenta and green, respectively. Green circles and red diamonds indicate the artificially introduced initiation and termination codons, respectively. Frames shown in cyan are interrupted by the artificial termination codons that prevent expression of the fluorescent reporters. (C--F) Fluorescent images show expression patterns of E7a-mCherry (C) and E7b-EGFP (D) under the control of the ubiquitous *eef-1A.1* promoter. A merged image with mCherry in red and EGFP in green is shown in E. A DIC image is shown in F. Bar, 100 μm. (G--I) Expression patterns of E7a-mCherry (G) and E7b-EGFP (H) in the head region under the control of the *myo-3* promoter were determined. A merged image with mCherry in red and EGFP in green is shown in I. Muscle cells in one of the four quadrants are numbered according to [@B38]. Bar, 10 μm. (J, K) Relative fluorescence intensity of E7a-mCherry (J) and E7b-EGFP (K). Fluorescence intensity in the cytoplasm of indicated muscle cells were measured by ImageJ, and relative fluorescence intensity was calculated by setting the values of cells 1/2 for E7a-mCherry or 7/8 for E7b-EGFP as 1 (*n* = 12). Boxes represent the range of the 25th and 75th percentiles, with the medians marked by solid horizontal lines, and whiskers indicate the 10th and 90th percentiles.](mbc-29-1075-g002){#F2}

Missense mutations in exons 7a and 7b cause contractile phenotypes in different subsets of muscle cells
-------------------------------------------------------------------------------------------------------

To determine the in vivo functions of tropomyosin isoforms containing E7a or E7b sequence, we examined phenotypes caused by a mutation in either E7a or E7b. *lev-11(x12)* is one of the original *lev-11* mutant alleles ([@B51]) and has a missense mutation in E7b ([@B45]) resulting in E234K in the LEV-11A isoform ([Figure 1C](#F1){ref-type="fig"}). We found that *lev-11(gk334531)*, one of the alleles from the Million Mutation Project ([@B83]), has a missense mutation in E7a that results in E196K in the LEV-11O isoform ([Figure 1C](#F1){ref-type="fig"}). The strain that possesses *lev-11(gk334531)* was outcrossed six times with the wild type and used in the following experiments. E196 and E234 correspond to *g* and *c* positions in a heptad, which are exposed on the surface of a coiled coil ([@B12]; [@B57]; [@B9], [@B8]). Calculation of coiled-coil probability by COILS ([@B54]) suggests that both of these missense mutations do not alter the coiled-coil formation of the tropomyosin molecule.

To determine biochemical properties of tropomyosin isoforms and effects of exon 7 mutations, we purified recombinant LEV-11A (with the E7b-encoded sequence) and LEV-11O (with the E7a-­encoded sequence) in wild-type and mutant forms ([Figure 3A](#F3){ref-type="fig"}) and examined their binding to actin. Their affinity to actin filaments was determined by actin cosedimentation assays ([Figure 3, B--F](#F3){ref-type="fig"}). In the absence of actin filaments, all examined LEV-11 proteins remained in the supernatants after ultracentrifugation ([Figure 3B](#F3){ref-type="fig"}, lanes 1, 3, 5, and 7). However, in the presence of actin filaments, all examined LEV-11 proteins coprecipitated with actin and were depleted from their respective supernatant ([Figure 3](#F3){ref-type="fig"}, lanes 2, 4, 6, and 8). Using this cosedimentation assay, binding of LEV-11 proteins with actin was quantitatively analyzed ([Figure 3, C--F](#F3){ref-type="fig"}). Wild-type LEV-11A bound to actin with high affinity ([Figure 3C](#F3){ref-type="fig"}), while LEV-11A(E234K) showed an ∼3-fold decrease in the affinity to actin ([Figure 3D](#F3){ref-type="fig"}). Wild-type LEV-11O showed a slightly lower affinity to actin than wild-type LEV-11A ([Figure 3E](#F3){ref-type="fig"}), and LEV-11O(E196K) bound to actin in a similar manner to wild-type LEV-11O ([Figure 3F](#F3){ref-type="fig"}). Despite the noticeable difference in dissociation constants (*K*~D~) between wild-type LEV-11A and LEV-11A(E234K), a statistical test using one-way analysis of variance (ANOVA) or Student's *t* test gave *p* = 0.1 for comparison between wild-type LEV-11A and LEV-11A(E234K), suggesting that the difference was insignificant or very minor. All examined LEV-11 proteins showed saturable binding to actin at LEV-11/actin molar ratios of 0.14--0.16, suggesting a 1:6 or 1:7 binding of LEV-11 to actin with no detectable difference among isoforms and mutations. Hill coefficients (*n*~H~) for binding of LEV-11 proteins to actin were estimated to be 2.5--3.4 ([Figure 3, C--F](#F3){ref-type="fig"}) suggesting that all examined LEV-11 proteins bound to actin with similar positive cooperativity. These results indicate that wild-type LEV-11A and wild-type LEV-11O bind to actin filaments in a manner similar to that for conventional high-molecular-weight tropomyosins, and that E234K but not E196K had a minor effect on the affinity to actin.

![Binding of LEV-11 isoforms and mutants to actin filaments. (A) Purified actin (0.8 μg) and recombinant LEV-11 proteins (1.0 μg each) were analyzed by SDS--PAGE. Molecular size markers in kDa (lane M) are shown on the left of the gel. (B) LEV-11 proteins (0.25 μM) were incubated without (--) or with (+) 5 μM F-actin for 1 h and ultracentrifuged. Supernatants (top panel) and pellets (bottom panel) were analyzed by SDS--PAGE (lanes 1--8). A control with actin alone is shown in lanes 9 and 10. All examined LEV-11 proteins remained in the supernatants in the absence of actin but precipitated in the presence of actin. Note that LEV-11A(E234K) could not be resolved from actin in the pellet but was clearly depleted from the supernatant (lane 4). Only size markers of 45 kDa (lane M) are included. (C--F) Quantitative analysis of actin binding of LEV-11 proteins was performed at various concentrations of LEV-11 proteins and a fixed concentration of actin (5 μM). Molar ratios of bound LEV-11 to actin were plotted as functions of free LEV-11 concentrations. The data were fitted to a Hill equation, and estimated dissociation constants (*K*~D~) and Hill constants (*n*~H~) are shown (means ± SD, *n* = 3). The graphs show representative results among three independent experiments.](mbc-29-1075-g003){#F3}

Expression and subcellular localization of LEV-11 proteins were examined in these strains by immunofluorescence microscopy ([Figure 4](#F4){ref-type="fig"}). The anti-LEV-11 antibody that we have previously generated reacts with all known LEV-11 isoforms ([@B65]). In the wild type, the LEV-11 proteins colocalized with actin in sarcomeres in the body wall muscle cells of both the head ([Figure 4, A--C](#F4){ref-type="fig"}) and main-body regions ([Figure 4, J--L](#F4){ref-type="fig"}), suggesting that both E7a- and E7b-containing LEV-11 isoforms are components of the thin filaments in muscle sarcomeres. These patterns were not noticeably different in *lev-11(gk334531)-E7a(E196K)* or *lev-11(x12)-E7b(E234K)* in the head ([Figure 4, D--I](#F4){ref-type="fig"}) or main-body regions ([Figure 4, M--R](#F4){ref-type="fig"}), indicating that these missense mutations do not cause major changes in the protein levels or the localization patterns of LEV-11 protein isoforms.

![Localization of LEV-11 and actin in the body wall muscle. Wild-type (A--C, J--L), *lev-11(gk334531)-E7a(E196K)* (D--F, M--O), and *lev-11(x12)-E7b(E234K)* (G--I, P--R) adult worms were immunofluorescently stained for LEV-11 (left column) and actin (middle column), and the head (A--I) and midbody (J--R) regions were examined at high magnification. Merged images are shown in the right column (LEV-11 in green and actin in red). Bar, 10 μm.](mbc-29-1075-g004){#F4}

Motility examination of the *lev-11* mutant worms in the absence or presence of levamisole, which is an agonist of the ACh receptor, demonstrated that both E7a and E7b are important for muscle contractility in the main body ([Figure 5](#F5){ref-type="fig"}). Original *lev-11* alleles, including *lev-11(x12)-E7b(E234K)*, were isolated in a screen for mutants that were resistant to levamisole ([@B51]). Wild-type worms crawled in a sinusoidal pattern on control agar plates ([Figure 5A](#F5){ref-type="fig"}); however, levamisole induced tonic body contraction and paralysis within a few minutes ([Figure 5, D and G](#F5){ref-type="fig"}). *lev-11(x12)-E7b(E234K)* worms crawled in a similar manner to the wild type on control agar plates ([Figure 5B](#F5){ref-type="fig"}), although they exhibited minor twitching of their bodies and moved slightly faster than the wild type ([Figure 5G](#F5){ref-type="fig"}). Unlike the wild type, these mutant worms were resistant to levamisole and continued to move in the presence of levamisole ([Figure 5, E and G](#F5){ref-type="fig"}) as reported by Lewis *et al.* ([@B51]). In contrast, *lev-11(gk334531)-E7a(E196K)* worms appeared to move normally on control agar plates ([Figure 5C](#F5){ref-type="fig"}), but quantitative analysis showed that they moved slightly slower than the wild type ([Figure 5G](#F5){ref-type="fig"}), indicating that the mutation in E7a partially impaired muscle contractility in the main body region. In the presence of levamisole, the worms with the E7a mutation were paralyzed, as well as the wild type ([Figure 5, F and G](#F5){ref-type="fig"}).

![Differential responses to levamisole in the main body region caused by *lev-11* exon 7 mutations. Wild-type (left), *lev-11(x12)-E7b(E234K)* (middle), and *lev-11(gk334531)-E7a(E196K)* (right) adult worms were treated with M9 buffer without (control) or with 500 μM levamisole (+ levamisole). (A--F) Entire worm bodies on agar plates are shown. The heads of the worms are oriented to the left. Bar, 300 μm. (G) Box plots of worm motility. Worm motility was quantified as beats per 30 s (*n* = 20). Boxes represent the range of the 25th and 75th percentiles, with the medians marked by solid horizontal lines, and whiskers indicate the 10th and 90th percentiles. NS, not significant. \*\*\*, *p* \< 0.001.](mbc-29-1075-g005){#F5}

Interestingly, the *lev-11* mutant worms exhibited different levamisole sensitivity in the head region, suggesting a functional difference between E7a and E7b in head muscle contractility ([Figure 6](#F6){ref-type="fig"}). In wild-type worms, the head region became contracted in the presence of levamisole ([Figure 6, A and D](#F6){ref-type="fig"}). Upon contraction, the head angle increased from ∼23° to ∼47° ([Figure 6, G and H](#F6){ref-type="fig"}). The very tip of the head of the *lev-11(x12)-E7b(E234K)* worms also showed a contracted appearance in the presence of levamisole ([Figure 6, B and E](#F6){ref-type="fig"}) to an extent similar to that in the wild type ([Figure 6H](#F6){ref-type="fig"}), indicating that these worms are levamisole-sensitive only in the head. In contrast, the *lev-11(gk334531)-E7a(E196K)* worms exhibited a relaxed appearance in the head in the absence or presence of levamisole ([Figure 6, C, F, and H](#F6){ref-type="fig"}). Therefore, *lev-11(gk334531)-E7a(E196K)* worms were resistant to levamisole in the head region but not in the main body. These results are consistent with the predominant selection of E7a in the head muscle cells ([Figure 2](#F2){ref-type="fig"}), suggesting that a tropomyosin isoform containing the E7a-encoded sequence, that is, LEV-11O, plays a major role in the regulation of head-muscle contractility.

![Differential responses to levamisole in the head region caused by *lev-11* exon 7 mutations. Wild-type (left), *lev-11(x12)-E7b(E234K)* (middle), and *lev-11(gk334531)-E7a(E196K)* (right) adult worms were treated with M9 buffer without (control) or with 500 μM levamisole (+ levamisole). (A--F) The head regions of mounted worms were imaged with DIC microscopy. Bar, 100 μm. (G) The head angle was defined as an angle (*a*) of a line drawn at the tip of a worm head from a midline. (H) Box plots of head angles. Head angles were measured using ImageJ (*n* = 10--22). Boxes represent the range of the 25th and 75th percentiles, with the medians marked by solid horizontal lines, and whiskers indicate the 10th and 90th percentiles. NS, not significant. \*\*\*, *p* \< 0.001.](mbc-29-1075-g006){#F6}

Compatibility of tropomyosin isoforms in muscle contractility regulation was further examined by altering their expression levels by transgenic overexpression. GFP-tagged LEV-11A (E7b) or LEV-11O (E7a) was expressed in wild-type background under the control of the *myo-3* promoter, which is active in all body wall muscle cells ([@B61]). Western blot showed that GFP-LEV-11A or GFP-LEV-11O was overexpressed in the transgenic strains ([Figure 7A](#F7){ref-type="fig"}). GFP-LEV-11A or GFP-LEV-11O was expressed in both head and midbody regions and localized in sarcomeric patterns ([Figure 7, B--E](#F7){ref-type="fig"}). Under normal (control) conditions, the worms expressing GFP-LEV-11A or GFP-LEV-11O moved slightly more slowly than the wild-type worms ([Figure 7, F--H and L](#F7){ref-type="fig"}). In the presence of levamisole, the worms expressing GFP-LEV-11A were paralyzed ([Figure 7, J and L](#F7){ref-type="fig"}) in a manner similar to that of wild-type worms ([Figure 7, I and L](#F7){ref-type="fig"}). However, the worms expressing GFP-LEV-11O could maintain a curved appearance of the body ([Figure 7K](#F7){ref-type="fig"}) and move very slowly ([Figure 7L](#F7){ref-type="fig"}) even in the presence of levamisole, indicating that overexpression of GFP-LEV-11O in the body conferred partial levamisole resistance. In contrast, expression of GFP-LEV-11A or GFP-LEV-11O did not affect levamisole-induced contraction of the heads ([Figure 7, I--K insets and M](#F7){ref-type="fig"}). Similar phenotypes were observed in at least one independent transgenic line for GFP-LEV-11A or GFP-LEV-11O (unpublished data). Therefore, contractility regulation in the main body region is sensitive to misexpression of LEV-11O (E7a), whereas that in the head muscle is tolerant to disturbance of tropomyosin isoforms.

![Effects of overexpression of LEV-11 isoforms on levamisole sensitivity. GFP-LEV-11A or GFP-LEV-11O was overexpressed in all muscle cells using the *myo-3* promoter in the wild-type background. (A) Western blot analysis of GFP-tagged and endogenous LEV-11 proteins. Lysates of 15 adult worms from each strain were subjected to Western blot with anti-LEV-11 antibody (top). The blotted membrane was stained with Coomassie Brilliant Blue (bottom), which demonstrated equivalent loading of total proteins. Positions of GFP-LEV-11 and endogenous LEV-11 proteins are shown on the right. Molecular size markers (lane M) in kDa are indicated on the left. (B--E) Localization of GFP-LEV-11A (B, D) or GFP-LEV-11O (C, E) in the head (B, C) or midbody (D, E) regions in live worms. Bar, 20 μm. (F--K) Wild-type worms (F, I) or worms expressing GFP-LEV-11A (G, J) or GFP-LEV-11O (H, K) were treated with M9 buffer without (control) or with 500 μM levamisole (+ levamisole). Entire bodies on agar plates and head regions of mounted worms (insets) are shown. Black bar, 500 μm for images of entire bodies. White bar, 100 μm for insets. (L, M) Box plots of worm motility (beats per 30 s, *n* = 20) (L) and head angles (*n* = 7--13) (M) are shown. Boxes represent the range of the 25th and 75th percentiles, with the medians marked by solid horizontal lines, and whiskers indicate the 10th and 90th percentiles. NS, not significant. \*, 0.01\< *p* \< 0.05. \*\*\*, *p* \< 0.001.](mbc-29-1075-g007){#F7}

*unc-27* troponin I mediates levamisole resistance in the main bodies of *lev-11* E7b mutant worms
--------------------------------------------------------------------------------------------------

To elucidate the mechanism of differential responses to levamisole in the head and main body, we examined the involvement of troponin I isoforms. The troponin complex, consisting of troponin T, troponin I, and troponin C, is a calcium-dependent regulator for muscle contraction ([@B22]). *C. elegans* has four genes encoding troponin I, a troponin component that cooperates with tropomyosin to inhibit actomyosin interaction ([@B14]; [@B70]; [@B60]; [@B7]). Among them, *tni-3* is preferentially expressed in the head region, whereas *unc-27* (also known as *tni-2*) is expressed as a major isoform in most of body wall muscle cells ([@B14]; [@B70]). Although expression patterns of *tni-3* and *unc-27* in the head have not been analyzed at single-cell levels, their expression patterns resemble the selection patterns or E7a (LEV-11O) and E7b (LEV-11A), suggesting isoform-specific compatibility for tropomyosin and troponin I.

RNAi of *tni-3* or *unc-27* in *lev-11* mutants revealed a compatible combination of troponin I and tropomyosin isoforms in the main body ([Figure 8](#F8){ref-type="fig"}). Wild-type worms were levamisole-sensitive in the head and body in control RNAi, *tni-3(RNAi)*, or *unc-27(RNAi)* ([Figure 8](#F8){ref-type="fig"} left column). *lev-11(x12)-E7b(E234K)* worms were resistant to levamisole in the body in control RNAi or *tni-3(RNAi)* ([Figure 8, B, E, H, and K](#F8){ref-type="fig"}) but became sensitive to levamisole in *unc-27(RNAi)* ([Figure 8, N and Q](#F8){ref-type="fig"}), indicating that the levamisole-resistant phenotype in the body of *lev-11(x12)-E7b(E234K)* was dependent on *unc-27* troponin I. *lev-11(x12)-E7b(E234K)* worms remained levamisole-sensitive in the head in control RNAi, *tni-3(RNAi)*, or *unc-27(RNAi)* ([Figure 8](#F8){ref-type="fig"}, insets in the middle column). Levamisole sensitivity of *lev-11(gk334531)-E7a(E196K)* worms was not modified by the RNAi treatments ([Figure 8](#F8){ref-type="fig"}, right column). Although lack of phenotypic modification by RNAi does not rule out functional significance in the genetic interaction between *lev-11o* and *tni-3*, these results, at least, show a close relationship between LEV-11A (E7b) tropomyosin and UNC-27 troponin I isoforms in the regulation of muscle contractility in the main-body region.

![Effects of RNAi of troponin I isoforms on levamisole sensitivity. Wild-type (left column), *lev-11(x12)-E7b(E234K)* (middle column), or *lev-11(gk334531)-E7a(E196K)* (right column) worms were treated with control RNAi (A--F), *tni-3(RNAi)* (G--L), or *unc-27(RNAi)* (M--R) and with M9 buffer without (control) or with 500 μM levamisole (+ levamisole). Entire bodies on agar plates and head regions of mounted worms (insets) are shown. The heads of the worms are oriented to the left. Black bars, 500 μm for images of entire bodies. White bars, 100 μm for insets.](mbc-29-1075-g008){#F8}

DISCUSSION
==========

In this study, we identified the LEV-11O tropomyosin isoform, which is the first isoform containing the E7a-encoded sequence. E7a was selected predominantly in the most anterior subset of the body wall muscle cells in the head, whereas E7b was selected in the rest of the muscle cells in the main body. Missense mutation in E7a or E7b caused levamisole-resistant phenotypes in the body regions where a corresponding exon is predominantly selected. Transgenic expression of LEV-11O in all muscle cells caused abnormal muscle contractility only in the main body. These results suggest that cell-specific alternative splicing of E7a and E7b is important to express appropriate tropomyosin isoforms for the regulation of muscle contraction.

LEV-11O (E7a) and LEV-11A (E7b) are different only by seven amino acids in the exon 7--encoded region ([Figure 1C](#F1){ref-type="fig"}), which may confer different biophysical properties on the tropomyosin molecules. Tropomyosin is nearly entirely composed of coiled coil that is based on seven-residue (heptad) repeats (typically labeled as *abcdefg*). Residues *a* and *d* of a heptad repeat are often hydrophobic and contribute to formation of a hydrophobic core that stabilizes a tropomyosin dimer ([@B34]). However, crystal structures of rat skeletal muscle α-tropomyosin fragments revealed several "broken cores" where the two polypeptide chains are separated and the coiled coil is locally unwound ([@B57]). In particular, the charged side chain of E218 at residue *a* of the heptad at residues 218--224 causes destabilization of the coiled coil and makes the molecule locally flexible ([@B57]). Interestingly, the corresponding heptads in LEV-11O and LEV-11A exhibit the greatest difference in coiled-coil probability ([Figure 1D](#F1){ref-type="fig"}). Because bending ([@B12]) and local destabilization of the coiled coil ([@B75], [@B76]) are important to adapt the shape of tropomyosin to fit with the helical structure of actin filaments, a difference in the coiled-coil stability may alter the actin-regulatory functions of the tropomyosin isoforms. Although we did not detect a difference between LEV-11O and LEV-11A in the affinity with actin in vitro, there may be a significant difference in muscle thin filament regulation in the presence of troponin in vivo. In thin filaments, tropomyosin binds to actin only weakly, with a distance of ∼10 Å from the surface of actin to allow rapid troponin-regulated movement ([@B41]; [@B24]; [@B71]). Therefore, the difference between a heptad of LEV-11O and LEV-11A may affect their dynamic biophysical properties, which may be of functional significance.

The specific selection of E7a in the limited head muscle cells suggests that the anteriormost muscle cells need to have different physiological properties than the rest of the muscle cells. The four most anterior muscle cells (cells 1--4) in each quadrant are innervated only by the nerve ring motor neurons, whereas all other muscle cells are innervated by the ventral nerve cord motor neurons (cells 5--8 receive innervation from both the nerve ring and the ventral nerve cord) ([@B94]). Because movement of the head is important in determining the direction of worm locomotion, the head muscle may have unique contractile properties in response to environmental cues to set a direction of movement. The roles of sensory neurons in the worm head during chemotaxis, thermotaxis, and mechanosensation have been extensively studied ([@B6]; [@B5]; [@B33]). However, how the head muscle is regulated during these behavioral changes remains largely unknown. A recent single-cell transcriptional profiling study has revealed different gene expression profiles between anterior and posterior body wall muscle cells ([@B15]), indicating that the muscle cells in the head are qualitatively different from the rest of the muscle cells. In addition to these trans­criptional regulation, head muscle--specific alternative splicing, such as E7a and E7b of *lev-11*, should further increase the complexity of differential gene products.

The RNAi experiments on troponin I isoforms suggest that isoform compatibility of tropomyosin and troponin may be involved in the regulation of differential muscle contractility between the head and body regions. Two troponin I genes, *unc-27* and *tni-3*, show patterns of region-specific expression similar to those of E7a/E7b splicing: *tni-3* is strongly expressed in the head region, whereas *unc-27* is predominantly expressed in most of the body wall muscle cells ([@B14]; [@B70]). Our observation that *unc-27(RNAi)* suppresses the levamisole resistance of *lev-11(x12)-E7b(E234K)* suggests that UNC-27 troponin I and LEV-11A (E7b) tropomyosin are one of the compatible isoform combinations. Lack of phenotypic modifications by *tni-3(RNAi)* could be due to insufficient depletion of the TNI-3 protein. [@B70] reported abnormal body morphology caused by *tni-3(RNAi)* by means of RNA microinjection, but we did not detect this phenotype in our *tni-3(RNAi)* treatment by the feeding method. Our recent optogenetic analysis showed that *lev-11(x12)-E7b(E234K)* worms fail to maintain a contracted state, while cholinergic neurons are active ([@B43]). Additionally, *unc-27* troponin I is crucial for inducing muscle relaxation in the main body ([@B14]). Together, these phenotypes suggest that the *lev-11(x12)-E7b(E234K)* mutation destabilizes the contracted state during excitation--contraction coupling. In contrast, LEV-11O (E7a) is involved in contractility regulation in both head and body regions. Nevertheless, overexpression of LEV-11O (E7a) in the body region caused levamisole resistance, independent of an E7a mutation. Therefore, having the right balance of tropomyosin--troponin isoform composition may be important for proper regulation of muscle contractility. In vertebrates, multiple isoforms of troponin components are expressed in a muscle type--specific manner, and a number of isoform-specific posttranslational modifications are known to regulate their functions ([@B32]; [@B44]). However, isoform compatibility of tropomyosin and troponin in vitro and in vivo is poorly understood. As studies in the fruit fly *Drosophila* revealed nonequivalent functions of troponin C isoforms in muscle contractility ([@B23]; [@B16]), *C. elegans* should also be a powerful model organism to address these questions. In addition to four troponin I isoforms, the *C. elegans* genome contains two genes for troponin C ([@B82]) and four genes for troponin T ([@B59]; [@B2]), which could potentially generate a large number of functionally distinct troponin--tropomyosin variants.

MATERIALS AND METHODS
=====================

Worm culture and microscopy
---------------------------

Worms were cultured following standard methods ([@B80]). The following strains were obtained from the *Caenorhabditis* Genetics Center and used in this study: N2 wild type, ZZ12 *lev-11(x12)* ([@B51]), and VC20516 a Million Mutation Project strain containing *lev-11(gk334531)* ([@B83]). VC20516 was outcrossed with wild type six times to isolate ON315 *lev-11(gk334531)* before phenotypic analysis. All mutant strains were analyzed as homozygotic hermaphrodites. Transgenic worms were generated as described previously ([@B47]). Genotypes of strains are listed in Supplemental Table S1.

RT-PCR and sequencing
---------------------

Total RNAs from synchronized L1-stage worms were extracted as described previously ([@B47], [@B50]). RT-PCR was performed essentially as described previously ([@B47], [@B50]).The sequences of the primers used in the RT-PCR experiments are available in Supplemental Table S2. RT-PCR products were analyzed by using a 2100 BioAnalyzer (Agilent Technologies). The sequences of the RT-PCR products were confirmed by direct sequencing or by cloning and sequencing.

Cloning of the *lev-11o* cDNA
-----------------------------

First-strand cDNAs were reverse-transcribed from total RNAs from the N2 strain using oligo-dT by a Maxima H^-^ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific). *lev-11* cDNAs were amplified by PCR using a primer pair for E1 and E9c with Platinum *Taq* DNA polymerase (Thermo Fisher Scientific), purified by a PCR Cleanup kit (Qiagen), and digested by *Bst*YI (New England BioLabs) that specifically recognized E7b. *Bst*YI-resistant cDNAs were amplified by PCR using the same primer set and cloned in a pET-3d plasmid vector (EMD MilliporeA) by an In-Fusion HD Cloning kit (Takara Bio USA). Isolated cDNA clones were confirmed by DNA sequencing.

Construction of expression vectors for *C. elegans* genes and cDNAs
-------------------------------------------------------------------

Fluorescence *lev-11* splicing reporter minigenes were constructed essentially as described previously ([@B47], [@B49]). Briefly, the *lev-11* genomic DNA fragment was cloned into a Gateway pENTR-L1/R5 vector (Life Technologies). Mutagenesis in the exons were performed with PrimeStar GXL DNA polymerase (Takara Bio, Shiga, Japan). Expression vectors were constructed by homologous recombination between the genomic DNA cassette and a fluorescent protein cassette in the pENTR-L1/R5 vector and a destination vector pDEST-*eef-1A.1p* or pDEST-*myo-3p* ([@B46]) with LR Clonase II Plus (Life Technologies). Expression vectors for GFP-LEV-11A and GFP-LEV-11O were constructed by inserting LEV-11A or LEV-11O cDNA at the *Eco*RI*-Nhe*I sites of pPD118.20 (provided by Andrew Fire, Stanford University) in-frame with the 3′-end of the GFP coding sequence. Briefly, the cDNA was amplified by PCR using Platinum *Taq* DNA polymerase High Fidelity (Thermo Fisher Scientific) and fused with pPD118.20 that had been cut with *Eco*RI and *Nhe*I using the In-fusion HD Cloning Kit (Takara Bio USA). The sequences of the primers used in the plasmid construction and mutagenesis are available in Supplemental Table S3. Genotypes of generated strains are listed in Supplemental Table S1. Sequence information on the reporter minigenes is available upon request to H.K.

Immunofluorescence staining
---------------------------

Adult hermaphrodites were fixed using a whole-mount method ([@B26]) and stained with anti--*C. elegans* tropomyosin (LEV-11) guinea pig polyclonal antibody ([@B65]) and anti-­actin mouse monoclonal antibody (C4, MP Biochemicals). The primary antibodies were further labeled with Alexa 488--conjugated goat anti-guinea pig immunoglobulin G (IgG) (Life Technologies) and Cy3-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories).

Fluorescence microscopy
-----------------------

Some of the images of fluorescence reporter worms were captured using a fluorescence compound microscope (DM6000B; Leica Microsystems, Wetzlar, Germany) equipped with a color-cooled CCD camera (DFC310FX; Leica Microsystems, Wetzlar, Germany). High-magnification images of fluorescence reporter worms and immunofluorescence staining were taken by a fluorescence inverted microscope (TE2000; Nikon Instruments, Tokyo, Japan) equipped with a SPOT RT monochrome CCD camera (Diagnostic Instruments). Images were processed with Photoshop CS3 (Adobe). The fluorescence intensity of mCherry ([Figure 2J](#F2){ref-type="fig"}) or EGFP ([Figure 2K](#F2){ref-type="fig"}) was measured with ImageJ. In a digital image (TIFF format), a straight line was drawn across a short axis at the center of each muscle cell, and the mean intensity was measured with the *Measure* tool of ImageJ. Then the relative fluorescence intensity was calculated by setting the values of cells 1/2 for E7a-mCherry or 7/8 for E7b-EGFP as 1.

Levamisole sensitivity assay
----------------------------

Adult worms were transferred into droplets of M9 buffer with or without 500 μM levamisole and incubated for 10 min on agar plates for observation of whole bodies or mounted immediately on 2% agarose pads for observation of head regions. Images of whole bodies were captured using a stereomicroscope (Stemi 2000C; Zeiss, Oberkochen, Germany) equipped with a digital camera (CoolPix 995; Nikon Corporation, Tokyo, Japan). Images of head regions were captured using an inverted microscope with differential interference contrast (DIC) optics (TE2000; Nikon Instruments, Tokyo, Japan) equipped with a SPOT RT monochrome CCD camera (Diagnostic Instruments). Worm motility was determined by counting swinging motions of worms in M9 buffer as described ([@B25]; [@B64]). Head angles were measured by the angle tool in ImageJ. The data were analyzed by one-way ANOVA using SigmaPlot 13 (Systat Software).

Preparation of proteins
-----------------------

Actin was prepared from rabbit skeletal muscle acetone powder (Pel-Freeze Biologicals) as described by [@B66]. cDNAs for LEV-11A and LEV-11O were amplified by RT-PCR and cloned into a pET-3d vector as described above. The PCR primers included codons for Ala-Ser after the initiator Met to mimic the N-terminal acetylation state of tropomyosin ([@B58]; Supplemental Table S2). Expression vectors for LEV-11A(E234K) and LEV-11O(E196K) were generated by site-directed mutagenesis using a QuickChange mutagenesis kit (Agilent Technologies). All insert sequences were verified by DNA sequencing. All LEV-11 proteins were bacterially expressed and purified in essentially the same manner. *Escherichia coli* BL21(DE3) cells were transformed with the LEV-11 expression vectors, and protein expression was induced by 0.4 mM isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside for 3 h at 37°C. The cells were harvested by centrifugation at 5000 × *g* for 10 min at 4°C and homogenized by sonication in 0.1 M NaCl, 1 mM EDTA, 20 mM Tris-HCl, pH 8.0, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 0.2 mM dithiothreitol (DTT). The homogenates were cleared at 20,000 × *g* for 30 min at 4°C, mixed with 35% saturation of ammonium sulfate for 30 min with stirring, and centrifuged at 20,000 × *g* for 30 min at 4°C. Each supernatant was dialyzed against 0.1 M NaCl, 20 mM Tris-HCl, pH 6.8, applied to a DE53 anion exchange column, and eluted with a NaCl gradient from 0.1 to 0.6 M. Fractions containing LEV-11 proteins were applied to a Bio-Gel HTP hydroxyapatite column (Bio-Rad) and eluted with a gradient of phosphate from 0.01 to 0.3 M in the presence of 0.05 M KCl at pH 7.5. Fractions containing pure LEV-11 proteins were dialyzed against F-buffer (0.1 M KCl, 2 mM MgCl~2~, 20 mM HEPES-KOH, pH 7.5) containing 50% glycerol and stored at --20°C. Protein concentrations were determined by a BCA Protein Assay kit (Thermo Fisher Scientific). Molar concentrations of LEV-11 dimers were calculated using a molecular weight of 66,000.

Actin cosedimentation assay
---------------------------

Various concentrations of LEV-11 proteins were incubated with or without 5 μM F-actin in F-buffer for 1 h at room temperature and ultracentrifuged at 42,000 rpm for 20 min using a Beckman 42.2Ti rotor. Supernatants and pellets were separated, adjusted to the same volumes, and examined by SDS--PAGE (12% acrylamide gel). Protein markers (\#29458-24; Nacalai USA) were used as molecular mass markers. The gels were stained with Coomassie Brilliant Blue R-250 (National Diagnostics) and scanned by an Epson Perfection V700 scanner at 300 dpi. Because LEV-11 proteins migrated too close to actin in the pellet fractions (see [Figure 3B](#F3){ref-type="fig"}), actin-dependent depletion of LEV-11 proteins was densitometrically quantified by ImageJ from the supernatant fractions to estimate portions of LEV-11 proteins in the pellets. Actin-independent sedimentation of LEV-11 proteins was quantified from the experiments without actin and subtracted from the data. The data were fitted to the following Hill equation (three-parameter sigmoidal) using SigmaPlot 13 (Systat Software): where *v* = bound LEV-11 relative to actin (μM/μM), *n* = maximal bound LEV-11 relative to actin (μM/ μM), *n*~H~ = Hill coefficient, *K*~D~ = dissociation constant, and \[LEV-11\] = \[LEV-11\]~free~.

Western blot
------------

Fifteen adult worms were suspended in 15 μl of SDS lysis buffer (2% SDS, 80 mM Tris-HCl, 5% β-mercaptoethanol, 15% glycerol, 0.05% bromophenol blue, pH 6.8), heated at 97°C for 2 min, homogenized briefly by sonication, and subjected to SDS--PAGE (12% acrylamide gel). The proteins were transferred to a polyvinylidene difluoride membrane (Immobilon-P; Millipore). The membrane was blocked in 5% nonfat milk in phosphate-buffered saline (PBS) containing 0.1% Tween 20 (PBS-T) and incubated for 1 h with anti-*C. elegans* tropomyosin (LEV-11) guinea pig polyclonal antibody ([@B65]). After being washed with PBS-T, the membrane was treated with horseradish peroxidase--conjugated goat anti-guinea pig IgG (MP Biomedicals) for 1 h. The reactivity was detected with Chemi-Lumi One Ultra (Nacalai USA) and exposure to x-ray films. Finally, the membrane was stained with 0.1% Coomassie Brilliant Blue R-250 (National Diagnostics) in 50% methanol and washed in a destaining solution containing 10% acetic acid and 50% ethanol to visualize total proteins ([@B93]).

RNAi
----

RNAi experiments were performed by feeding with *Escherichia coli* HT115(DE3) expressing double-stranded RNA as described previously ([@B65]). All RNAi experiments were started by treating L4 larvae and observing phenotypes in the next generation. Control RNAi experiments were performed using the unmodified L4440 plasmid vector for feeding RNAi (kindly provided by Andrew Fire, Stanford University; [@B84]). RNA clones for *tni-3* (V-11A06) and *unc-27* (X-4O16) were obtained from Source BioScience (Nottingham, United Kingdom).
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